![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Rotavirus is the most frequent cause of severe diarrhoea in children aged <5 y. A prospective, multicentre, observational study was conducted in Europe during the 2004–2005 rotavirus season. The study was undertaken in areas of Belgium, France, Germany, Italy, Spain, Sweden, and the UK, to estimate the incidence of community-acquired acute gastroenteritis (AGE) and rotavirus gastroenteritis (RVGE) in children under 5 y of age seeking medical care in 3 settings: primary care, emergency department, and hospital. A post-hoc analysis was done to further describe the age distribution of children with RVGE. The study included 2846 children with AGE. Of 2712 children for whom ELISA results were available, 1102 (40.6%) were rotavirus-positive to the results section well. Overall, 86.1% of RVGE cases occurred in children aged between 3 months and 3 y, whereas 1.8% of cases were observed in infants aged less than 3 months. A total of 3.6% of cases occurred in children aged more than 4 y. These results suggest that, in Europe, routine vaccination for rotavirus should be offered to all infants in early childhood to be effective during the main at-risk period. This could significantly reduce the substantial burden of this potentially serious childhood disease.
Acknowledgments
The authors take full responsibility for the content of this contribution, but thank Communigen (Oxford, UK; supported by Sanofi Pasteur MSD) for assistance with preparation of the manuscript.
Financial support: The study was sponsored by Sanofi Pasteur MSD (study number X03-ROT-510).
Declaration of interest: Pierre Van Damme is the Chief and Principal Investigator for clinical trials conducted on behalf of the University of Antwerp (for which the University obtains research grants from vaccine manufacturers). Speaker's fees for presentations on vaccines are paid directly to an educational fund held by the University of Antwerp. Carlo Giaquinto is Head of the Paediatric Clinical Research Unit, Department of Paediatrics, University of Padua. He has received research grants from pharmaceutical companies and research manufacturers for epidemiological and clinical research. Dr Giaquinto is also a member of advisory boards of Sanofi Pasteur MSD and GlaxoSmithKline.